Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS
Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research
'Best ever' Alzheimer's drug 'set to be blocked for NHS use' due to cost pressures
An Alzheimer's drug deemed the "best ever" is set to be blocked for NHS use due to its high cost. Donanemab, manufactured by pharmaceutical giant Eli Lilly, is a targeted antibody drug which slows down the early stages of Alzheimer's.
Alzheimer's drug that slows down disease rejected for widespread use on the NHS
People will not be able to access the drug, which slows progression of the disease by four to seven months, on the NHS
Pioneering Alzheimer's drug rejected for widespread use in NHS in England
This is the second time a new Alzheimer's treatment has been rejected by the health spending watchdog in a matter of months.
Alzheimer's 'wonder drug' Donanemab blocked for use on NHS over cost concerns
Alzheimer's 'wonder drug' Donanemab blocked for use on NHS over cost concerns - Campaigners say decision is ‘frustrating setback’ for people living with disease
Lilly Alzheimer's drug not to be covered by U.K.'s NHS: report
U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early Alzheimer’s disease because it’s too expensive. Read more here.
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its costs.
Second Alzheimer’s ‘wonder drug’ blocked for use on NHS due to high costs
NHS spending watchdog says donanemab - available to 70,000 people in England and Wales - 'does not currently demonstrate value' for money
Eli Lilly Alzheimer’s drug rejected as too expensive by UK’s NHS, FT reports
The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being
England’s Drug-Cost Watchdog Rejects Eli Lilly’s Alzheimer’s Drug
Regulator cited significant uncertainties about the drug’s benefits, as well as the high costs to treat its severe side effects.
Live news: Second Alzheimer’s drug deemed too expensive for UK’s NHS
Keep abreast of significant corporate, financial and political developments around the world. Stay informed and spot emerging risks and opportunities with independent global reporting, expert commentary and analysis you can trust.
ALZFORUM2d
Lecanemab Tops Other Antibodies at Binding Soluble Aβ Aggregates
Lecanemab Favors Early Aggregates. Fluorescently labeled lecanemab (green) bound most strongly to soluble Aβ aggregates ...
Surrey Alzheimer's drug trial patient shares his experience of donanemab
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...
Outsourcing-pharma1d
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
Alzheimer’s wonder drug blocked on NHS over cost
The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for ...